FDA Investigator Anna Lazar

Anna Lazar has conducted inspections on 45 sites in 12 countries as of 26 Mar 2014. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
45
Last Inspection Date:
26 Mar 2014
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Germany, Hungary, Canada, Italy, Sweden, Japan, Czechia, Switzerland, Finland, France, United States of America, United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Anna Lazar:
Alan P Kurtzberg, Alberto A Viciedo, Alicia M Mozzachio, Allen F Hall, Anastasia M Shields, Angela E Glenn, Anissa M Vargas, Anita R Michael, Annet R Rajan, Anthony C Warchut, Ariel Cruz Figueroa, Arsen Karapetyan, Audrey Thereset Uy, Azza Talaat, Barbara J Rincon, Barbara Janine Breithaupt, Barbara M Frazier, Bogdan Kurtyka, Bonita S Chester, Brian D Young, Brooke K Higgins, Carl Lee, Carla A Norris, Carla J Lundi, Caryn M Mcnab, CDR Ileana Barreto Pettit, Charanjeet Jassal, Charisse K Green, Charles I Ann, Charles M Edwards, Charles R Cote, RIC, Cheryl Love Harris, Christine W Twohy, Cody D Rickman, Crayton Lee, Cynthia A Palmer, Dale A Nyberg, Daniel W Johnson, David A Oluwo, David M Beltran, Dennis Cantellops Paite, Dennis R Downer, Derek S Dealy, Doan T Nguyen, PharmD, Douglas C Kovacs, Dr. Zhihao Qiu (Peter), PhD, Edmund F Mrak, Jr, Edwin L Hobbs, Ellen P Madigan, Felix Maldonado, Francis A Guidry, Freddy Ortiz Colon, Frederick F Razzaghi, Gam S Zamil, Gerardo Z Vazquez, Ginger M Sykes, Gwyn G Dickinson, Ivis L Negron, James A Lane, James A Liubicich, James P Mcreavey, James P Stumpff, Jay T Wong, Jeffrey A Sommers, Joan T Briones, Jogy George, John P Mistler, Jorge L Guadalupe, Jose A Lopez, Jose Acruz Gonzalez, José E Meléndez, Jose M Cayuela, Jose R Hernandez, Joseph J Vannelli, Joseph T Dougherty, Joshua P Wireman, Judith A Paterson, Junho Pak, Justine Tomasso, Karen L Kosar, Karlton T Watson, Karyn M Campbell, Kellia N Hicks, Kelvin Cheung, Kenneth H Williams, Kevin A Gonzalez, Kevin P Foley, Khoa Nathanv Tran, Kim Lthomas Cruse, Kristen D Evans, Kristy A Zielny, Lance Mde Souza, MBA, Larry K Austin, Laurie B Frazier, Lawrence Harmon, Jr, LCDR Debra Emerson, LCDR Michael H Tollon, Lequita M Mayhew, Liatte Kreuger, PharmD, Lillie D Witcher, Lisa Shin, Luella J Rossi, Luis A Dasta, Lynnette I Riggio, Marcus F Yambot, Margaret M Annes, Maria A Ruttell, Maribeth G Niesen, Marie A Fadden, Mark R Mcclain, Martha Sullivan Myrick, Matthew B Casale, Matthew J Sienko, Matthew R Noonan, Maureen A Wentzel, Melissa J Garcia, Meredith L Sheridan, Michael A Charles, Michael L Chasey, Michael R Goga, Michael W Burd, Michele L Forster, PhD, Michele L Obert, Michele Perry Williams, Monica M Mcclure, Mra Davism, Mra M Barbosar, Mra Mcculloughj, Nancy M Lazzari, Nicholas A Violand, Nicholas L Paulin, Pal S Mayasandra, Parul M Patel, Patrick C Klotzbuecher, Paula A Trost, Raquel Gonzalez Rivera, Raymond T Oji, Reba A Gates, Rebecca E Dombrowski, Robert D Tollefsen, Robert J Martin, Robert W Mccullough, Rochelle L Cross, Rodney G Raiford, Rory K Geyer, Russell J Glapion, Russell K Riley, Saied A Asbagh, Santos E Camara, Sarah E Mcmullen, Sarah M Meng, Sarah M Napier, Scott T Ballard, Sharon Mills, Shirley J Berryman, Simone E Pitts, Sixto M Mercado Rios, Sneha S Patel, Sonia R Peterson, Stephanie A Slater, MS, Stephen J Mottola, Steven A Gonzales, Steven C Madzo, Steven M Weinman, Steven P Donald, Susan F Laska, MS, Tamil Arasu, PhD, Terri L Dodds, Thomas J Arista, Thomas W Nojek, Thuy T Nguyen, LCDR, Tiara Nbrown Crosen, Tiffani D Wilson, Timothy T Kapsala, Tina M Pawlowski, Tonya O Corbin, Torrance J Slayton, Truong Xuan Nguyen (Andy), Uduak M Inokon, Unnee Ranjan, Veronica Fuentes, MS, Victoria A Wagoner, Vilmary Negron Rodriguez, Vlada Matusovsky, Walden H Lee, Wendy G Tan, PhD, William J Leonard, Yong Hu, Yumi J Hiramine, Zhong Li, PhD

Anna Lazar's Documents

Publish Date Document Type Title
February, 2002 FDA 483 Pharmacia & Upjohn AB - Form 483, 2002-02-20
April, 2000 FDA 483 Response Patheon Inc. - Form 483R, 2000-08-29
October, 2002 EIR Carbogen-Amcis AG - EIR, 2002-10-09
November, 2002 FDA 483 Response Societa Italiana Medicinali Scandicci S.I.M.S. Srl - Form 483R, 2002-12-10
March, 2001 EIR Bayer Weimar GmbH und Co. KG - EIR, 2001-05-15
April, 2000 FDA 483 Global Pharm Inc. - Form 483, 2000-04-06
February, 2002 FDA 483 Pfizer Health AB - Form 483, 2002-02-25
June, 2001 EIR Fermion Oy - EIR, 2001-06-21
September, 2001 FDA 483 Olon SpA - Form 483, 2001-09-12
November, 2002 EIR Sanofi-Aventis Deutschland GmbH - EIR, 2003-01-31
November, 2002 EIR Societa Italiana Medicinali Scandicci S.I.M.S. Srl - EIR, 2002-12-20
September, 2001 EIR Rohm and Haas France S.A.S - EIR, 2001-11-09
October, 2002 FDA 483 Response Cu Chemie Uetikon GmbH - Form 483R, 2002-12-04
October, 2002 FDA 483 Response Carbogen-Amcis AG - Form 483R, 2002-11-15
February, 2002 FDA 483 Response Pfizer Health AB - Form 483R, 2002-03-15
October, 2002 EIR Cu Chemie Uetikon GmbH - EIR, 2002-10-17
September, 2003 FDA 483 Response Synthesia, a.s. - Form 483R, 2003-09-29
November, 2002 FDA 483 Societa Italiana Medicinali Scandicci (S.I.M.S. Srl) - Form 483, 2002-11-27
September, 2003 FDA 483 Aliachem a.s. - Form 483, 2003-09-10
February, 2002 EIR Pfizer Health AB - EIR, 2002-02-25
September, 2001 FDA 483 Response DSP - Form 483R, 2001-10-18
September, 2001 FDA 483 Response Olon SpA - Form 483R, 2001-09-26
September, 2003 EIR Synthesia, a.s. - EIR, 2003-10-17
October, 2000 FDA 483 Egis Pharmaceuticals Ltd. - Form 483, 2000-10-12
February, 2004 EIR Kyowa Hakko Bio Co. Ltd. - EIR, 2004-02-10
September, 2001 EIR Olon SpA - EIR, 2001-10-17
August, 2000 FDA 483 Response Teva Pharmaceutical Works Private Limited Company - Form 483R, 2000-12-04
September, 2001 FDA 483 Rohm and Haas France S.A.S - Form 483, 2001-09-19
October, 2000 FDA 483 Response Societa Italiana Medicinali Scandicci S.I.M.S. Srl - Form 483R, 2000-11-03
August, 2000 EIR Teva Pharmaceutical Works Private Limited Company - EIR, 2000-08-30
March, 2001 FDA 483 Schering GmbH - Form 483, 2001-03-22
October, 2000 EIR Societa Italiana Medicinali Scandicci S.I.M.S. Srl - EIR, 2000-10-20
April, 2000 EIR Patheon Inc. - EIR, 2000-08-23
February, 2004 EIR Fuji Chemical Industries Co., Ltd. - EIR, 2004-05-05
March, 2001 FDA 483 Response Bayer Weimar GmbH und Co. KG - Form 483R, 2001-04-03
October, 2000 FDA 483 Societa Italiana Medicinali Scandicci (S.I.M.S. Srl) - Form 483, 2000-10-20

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more